ECSP099315A - Inhibidores de cinasa - Google Patents

Inhibidores de cinasa

Info

Publication number
ECSP099315A
ECSP099315A EC2009009315A ECSP099315A ECSP099315A EC SP099315 A ECSP099315 A EC SP099315A EC 2009009315 A EC2009009315 A EC 2009009315A EC SP099315 A ECSP099315 A EC SP099315A EC SP099315 A ECSP099315 A EC SP099315A
Authority
EC
Ecuador
Prior art keywords
compounds
kinase inhibitors
methods
intermediaries
kinases
Prior art date
Application number
EC2009009315A
Other languages
English (en)
Inventor
Michael B Wallace
Jason Brown
Qing Dong
Bheema R Paraselli
Jeffrey Alan Stafford
Hasanthi Wijesekera
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/539,857 external-priority patent/US8119655B2/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP099315A publication Critical patent/ECSP099315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

RESUMEN DE LA INVENCIÓNSe proporcionan compuestos para uso con las cinasas que comprenden un compuesto seleccionado del grupo que consiste de la fórmula (I) en donde las variables son como se definen en la presente. También se proporcionan composiciones farmacéuticas, kits y artículos para manufactura que comprenden tales compuestos; métodos e intermediarios útiles para hacer los compuestos; y métodos de uso de los compuestos.
EC2009009315A 2006-10-09 2009-05-08 Inhibidores de cinasa ECSP099315A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/539,857 US8119655B2 (en) 2005-10-07 2006-10-09 Kinase inhibitors
PCT/US2006/039667 WO2007044779A1 (en) 2005-10-07 2006-10-10 Kinase inhibitors
US91262907P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
ECSP099315A true ECSP099315A (es) 2009-06-30

Family

ID=40719252

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009315A ECSP099315A (es) 2006-10-09 2009-05-08 Inhibidores de cinasa

Country Status (9)

Country Link
EP (3) EP2145877B1 (es)
KR (1) KR20090068277A (es)
AU (1) AU2007313961A1 (es)
CA (1) CA2666138A1 (es)
CR (1) CR10780A (es)
DO (1) DOP2009000073A (es)
EC (1) ECSP099315A (es)
NO (1) NO20091817L (es)
WO (1) WO2008054956A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2283014A1 (en) * 2008-04-16 2011-02-16 Takeda Pharmaceutical Company Limited Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyridoý2,3-b¨indole-7-carboxamideand methods of use therefor
WO2009129401A1 (en) * 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2297145A2 (en) * 2008-04-16 2011-03-23 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n- (1-methylpiperidin-4-yl)-9h-pyrido[2, 3-b]indole-7-carboxamide and methods of use therefor
PE20110365A1 (es) 2008-06-11 2011-07-11 Genentech Inc Diazacarbazoles como inhibidores de checkpoint quinasa 1 (chk1)
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CN112525878B (zh) * 2020-10-14 2023-05-16 辽宁石油化工大学 一种具有过滤功能sers基底的制备方法及应用
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
US20070004684A1 (en) * 2005-06-09 2007-01-04 Boehringer Ingelheim International Gmbh Alpha-Carbolines as CDK-1 inhibitors
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010500961A (ja) * 2006-08-02 2010-01-14 武田薬品工業株式会社 α−カルボリン誘導体およびその製造方法

Also Published As

Publication number Publication date
DOP2009000073A (es) 2018-02-28
KR20090068277A (ko) 2009-06-25
WO2008054956A2 (en) 2008-05-08
AU2007313961A1 (en) 2008-05-08
EP2145877B1 (en) 2012-10-03
EP2145877A2 (en) 2010-01-20
EP2079696A2 (en) 2009-07-22
EP2145878A3 (en) 2010-02-24
EP2145877A3 (en) 2010-02-24
EP2145878A2 (en) 2010-01-20
WO2008054956A3 (en) 2008-09-04
CA2666138A1 (en) 2008-05-08
CR10780A (es) 2009-06-05
AU2007313961A2 (en) 2009-06-11
NO20091817L (no) 2009-06-26

Similar Documents

Publication Publication Date Title
CR10780A (es) Inhibidores de cinasa
CR11370A (es) Inhibidores de quinasas simil polo
CR10937A (es) Inhibidores de cinasa mapk/erk
CR20110135A (es) INHIBIDORES DE cMET
NI201000198A (es) Compuestos triazina como inhibidores mtor y quinasa p13.
UY31830A (es) Activadores de glucoquinasa
ECSP10010434A (es) Inhibidores de hsp90
CR20130102A (es) Imidazopiridazinas sustituidas
CU20110052A7 (es) Compuestos orgánicos
CU23840B1 (es) Nuevos derivados de sulfonamida como antagonistas de la bradiquinina
CU20120059A7 (es) Compuestos de pirrolo[2,3-d]pirimidina
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
CO6290760A2 (es) Derivados de alcoholes de 1 fenil-2-piridinilalquilo como inbidores de la fosfodiesterasa
UY32077A (es) Inhibidores de quinasa tipo polo
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
CR10818A (es) Inhibidores de cinasa mapk/erk
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
WO2009129401A8 (en) Kinase inhibitors
NI201100035A (es) Agentes antifúngicos.
CO6331464A2 (es) Inhibidores de cinasa
CR10970A (es) Proceso e intermediarios para preparar arzoxifeno
UA99739C2 (ru) Ингибиторы polo-подобных киназ
CO6321260A2 (es) Derivados aromaticos de oxima como inhibidores de hsp90